Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

NCT03302234 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

568

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Ipilimumab
OTHER: Placebo

Sponsor

Merck Sharp & Dohme LLC